CHD1Li 6.11
CHD1Li 6.11 is a potent and orally active Chromodomain Helicase DNA Binding Protein 1 Like (CHD1L) (oncogenic gene) inhibitor (IC50 = 3.3 µM for cat-CHD1L recombinant protein) . CHD1Li 6.11 can inhibit EMT, induce mesenchymal-epithelial transition (reverse EMT) and promote apoptosis in tumor organoid models. CHD1Li 6.11 can be used for the research of cancer, such as colorectal cancer[1].
Product Specifications
CAS Number
2716890-91-2
UNSPSC
12352005
Target
Apoptosis; DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/chd1li-6-11.html
Purity
99.54
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(NC2=NC(N3CCCC3)=NC(C)=C2)C=C1)CC4=CC(Br)=CS4
Molecular Formula
C21H22BrN5OS
Molecular Weight
472.40
References & Citations
[1]Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65 (5) :3943-3961.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NRF1 (NRF1/2608), CF640R conjugate, 0.1mg/mL
GFAP (Astrocyte & Neural Stem Cell Marker) (rASTRO/789), CF740 conjugate, 0.1mg/mL
4-Chloro-3-nitro-5-sulfamoylbenzoic Acid Ammonium Salt
